Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43372
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Filippatos, Gerasimos | - |
dc.contributor.author | Gold, Michael R. | - |
dc.contributor.author | MULLENS, Wilfried | - |
dc.contributor.author | Kusano, Kengo | - |
dc.contributor.author | Hersi, Ahmad S. | - |
dc.contributor.author | Birnie, David | - |
dc.contributor.author | Gerritse, Bart | - |
dc.contributor.author | Leclercq, Christophe | - |
dc.date.accessioned | 2024-07-15T08:10:54Z | - |
dc.date.available | 2024-07-15T08:10:54Z | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-07-15T06:10:44Z | - |
dc.identifier.citation | The Lancet, 403 (10443) , p. 2484 -2485 | - |
dc.identifier.uri | http://hdl.handle.net/1942/43372 | - |
dc.description.abstract | whether the position of the left ventricular pacing is necessarily optimal. The left ventricular pacing lead position is important in relation to the clinical and mechanical response to CRT. Both lead placement, guided by cardiac imaging, 2 and positioning, determined by the electrical latency in intracardiac electrograms, 3 effectively improve the CRT response. The paced morphology of the electrograms recorded by the CRT device can reveal the effectiveness of the pacing. A highly effective CRT pacing rate is associated with a high prevalence of CRT responders and low risk of hospitalisation for heart failure. 4 We would like to know how the investigators determined the position of their left ventricular pacing leads for an effective adaptive CRT response. Alternatively, the investigators could have had the option of using multipolar leads, such as quadripolar leads, which do not require optimal lead positioning. Quadripolar leads are known to be associated with lower allcause mortality than conventional bipolar leads. 5 We declare no competing interests. | - |
dc.description.sponsorship | Medtronic; Novo Nordisc; Bayer; Boehringer Ingelheim; Servier; Vifor; | - |
dc.description.sponsorship | Cardior; Impulse Dynamics; EU; Biotronik; Medtronic Japan; Pfizer; | - |
dc.description.sponsorship | Biotronik Japan; Bristol Myers Squibb; Medtronic; Boston Scientific | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject.other | Humans | - |
dc.subject.other | Treatment Outcome | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | COVID-19 | - |
dc.title | Clinical outcomes of the AdaptResponse trial – Authors' reply | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 2485 | - |
dc.identifier.issue | 10443 | - |
dc.identifier.spage | 2484 | - |
dc.identifier.volume | 403 | - |
local.format.pages | 2 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Filippatos, G (corresponding author), Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Athens 12461, Greece. | - |
dc.description.notes | gfilippatos@gmail.com | - |
local.publisher.place | STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Letter | - |
dc.identifier.doi | 10.1016/S0140-6736(24)00866-3 | - |
dc.identifier.pmid | 38851281 | - |
dc.identifier.isi | 001252781200001 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Filippatos, Gerasimos] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Athens 12461, Greece. | - |
local.description.affiliation | [Gold, Michael R.] Med Univ South Carolina, Charleston, SC USA. | - |
local.description.affiliation | [Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium. | - |
local.description.affiliation | [Mullens, Wilfried] Hasselt Univ, Hasselt, Belgium. | - |
local.description.affiliation | [Kusano, Kengo] Natl Cerebral & Cardiovasc Ctr, Osaka, Japan. | - |
local.description.affiliation | [Hersi, Ahmad S.] King Saud Univ, Fac Med, Riyadh, Saudi Arabia. | - |
local.description.affiliation | [Birnie, David] Univ Ottawa Heart Inst, Ottawa, ON, Canada. | - |
local.description.affiliation | [Gerritse, Bart] Medtron Bakken Res Ctr, Maastricht, Netherlands. | - |
local.description.affiliation | [Leclercq, Christophe] Univ Rennes, Rennes, France. | - |
local.uhasselt.international | yes | - |
item.fulltext | With Fulltext | - |
item.fullcitation | Filippatos, Gerasimos; Gold, Michael R.; MULLENS, Wilfried; Kusano, Kengo; Hersi, Ahmad S.; Birnie, David; Gerritse, Bart & Leclercq, Christophe (2024) Clinical outcomes of the AdaptResponse trial – Authors' reply. In: The Lancet, 403 (10443) , p. 2484 -2485. | - |
item.accessRights | Restricted Access | - |
item.contributor | Filippatos, Gerasimos | - |
item.contributor | Gold, Michael R. | - |
item.contributor | MULLENS, Wilfried | - |
item.contributor | Kusano, Kengo | - |
item.contributor | Hersi, Ahmad S. | - |
item.contributor | Birnie, David | - |
item.contributor | Gerritse, Bart | - |
item.contributor | Leclercq, Christophe | - |
crisitem.journal.issn | 0140-6736 | - |
crisitem.journal.eissn | 1474-547X | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Clinical outcomes of the AdaptResponse trial .pdf Restricted Access | Published version | 44.9 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.